Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Yohei Doi, MD, PhD

Infectious Diseases

Professor of Medicine

Director, Center for Innovative Antimicrobial Therapy

Email: yod4@pitt.edu

Phone: 412-648-9445

Contact
Office: BST E1057
200 Lothrop Street
Pittsburgh, PA 15213
 
Phone: 412-648-9445
Fax: 412-648-8521
E-mail: yod4@pitt.edu
Administrative Assistant:
Jamira Watt
Address: 817 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Email: JRW185@pitt.edu
Phone: 412-624-9435
Fax: 412-648-8521
Education and Training
Education
Bachelor of Medicine, Nagoya University School of Medicine, 1998
Doctor of Medicine, Nagoya University School of Medicine, 2004
Training
Medicine, Anjo Kosei Hospital, 1998
Medicine, St. Luke's-Roosevelt Hospital Center, 2003
Infectious Diseases, University of Pittsburgh Medical Center, 2005
Research Interest
The mission of Dr. Doi's laboratory is to identify and investigate antimicrobial resistance of clinical concern among gram-negative bacterial pathogens. The areas of research include the genetic and molecular basis of emerging antimicrobial resistance mechanisms; the rapid diagnosis of resistance using phenotypic, genetic, and lipidomic approaches; and inhibitor-based drug discovery. Current efforts are focused on colistin resistance in Acinetobacter baumannii, a problematic healthcare-associated pathogen, and fosfomycin resistance in Escherichia coli, the predominant cause of urinary tract infection in both healthcare and community settings. The latter work has expanded into drug discovery effort aimed at reversing resistance using an inhibitor-based approach.
Clinical Interest
Dr. Doi rounds on the general infectious diseases consult services as an attending physician and provides teaching on antimicrobial resistance mechanisms.
Educational Interest
Dr. Doi is involved in the Medical Microbiology course for the first-year medical students.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Doi Y, Paterson DL, Egea P, Pascual A, López-Cerero L, Navarro MD, Adams-Haduch JM, Qureshi ZA, Sidjabat HE. Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, US, and Seville, Spain. Clin Microbiol Infect. 2009.
Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. Antimicrob Agents Chemother. 2009; 53: 3159-61.
Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A, Rodríguez-Baño J, Doi Y. Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis. 2009; 48: 739-44.
Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of KPC-type beta-lactamase using a boronic acid compound. J Clin Microbiol. 2008; 46: 4083-6.
Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008; 52: 3837-43.
Sponsored Research/Activities
Title: Colistin resistance in extensively drug-resistant Gram-negative pathogens
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI104895
Start Year: 2020
End Year: 2025
Title: Mechanisms of cefiderocol resistance
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI151362
Start Year: 2020
End Year: 2022
Title: MDRO: Study of Highly Resistant Escherichia coli (SHREC)
Role: Principal Investigator
Funding Agency: Duke University / National Institute of Health
Grant Number: UM1 AI104681
Start Year: 2020
End Year: 2021
Title: Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI135522
Start Year: 2018
End Year: 2020
Title: Colistin-Resistant Acinetobacter baumannii
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI104895
Start Year: 2014
End Year: 2019
Title: Biomarkers for Urinary Tract
Role: Co-Investigator
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: R01 DK118033
Start Year: 2019
End Year: 2024
Title: Assessment of Otopathogens in Young Children with Acute Otitis Media
Role: Co-Investigator
Funding Agency: Merck
Grant Number: RES
Start Year: 2019
End Year: 2021
Title: ARLG FOCUS
Role: Co-Investigator
Funding Agency: Duke University/ National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI104681
Start Year: 2018
End Year: 2019
Title: Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae (CRACKLE): a Prospective, Observational Cohort Study
Role: Co-Investigator
Funding Agency: Duke University
Grant Number: UM1 AI104681
Start Year: 2016
End Year: 2019
Title: Gram Negative ARLG Steering Committee Chair
Role: Consortium Principal Investigator
Funding Agency: Duke University / National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI104681
Start Year: 2019
End Year: 2020
Notable Achievements
Associate Editor
Antimicrobial Agents and Chemotherapy Editorial Board Member
Journal of Clinical Microbiology
Diagnostic Microbiology and Infectious Disease
Honoree, University of Pittsburgh Honors Convocation, 2015